Peter A Campochiaro

1 month ago | thelancet.com | Peter A Campochiaro |Robert Avery |David Brown

We thank Huixun Jia and Xiaodong Sun for their perspective on our study.1 The goals of this first-in-human trial were to identify safe doses of RGX-314 and an optimised protocol for advanced studies. Doses in cohorts 1 and 2 were very low, resulting in little expression of anti-vascular endothelial growth factor (VEGF) protein, and, reassuringly, supplemental anti-VEGF injections were needed (these cohorts were vector-treated controls).

Mar 27, 2024 | thelancet.com | Peter A Campochiaro |Robert Avery |David Brown

Summary Frequent anti-vascular endothelial growth factor A (VEGF-A) injections reduce the risk of rapid and severe vision loss in patients with neovascular age-related macular degeneration (nAMD); however, due to undertreatment, many patients lose vision over time. New treatments that provide sustained suppression of VEGF-A are needed.

Jun 5, 2023 | nature.com | Peter A Campochiaro

Vascular endothelial cell growth factor-A (VEGF-A) plays a major role in diabetic macular oedema (DMO) and intraocular injections of proteins that block VEGF-A are highly efficacious [1,2,3]. However, observational trials have shown that visual outcomes for DMO patients treated in clinical practice are substantially worse than visual outcomes obtained in clinical trials, and injection frequencies are lower [4].